Can I Take Folate with Leqvio (Inclisiran)?

How Inclisiran Works and Why It Rarely Interacts with Supplements

Inclisiran is a small interfering RNA (siRNA) therapeutic that targets PCSK9 messenger RNA inside liver cells. After a subcutaneous injection, the drug is taken up by hepatocytes via the GalNAc conjugate system, where it silences PCSK9 transcription for roughly six months per dose. The FDA approved inclisiran in December 2021 under the brand name Leqvio for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who need additional LDL-C lowering on top of maximally tolerated statin therapy. The FDA label [1] lists no drug-drug interactions driven by cytochrome P450 enzymes, P-glycoprotein, or plasma-protein displacement, because inclisiran does not meaningfully use those routes.

Why the Interaction Profile Is So Clean

Most supplement-drug interactions occur at four checkpoints: absorption, protein binding, hepatic metabolism (primarily CYP450 enzymes), and renal clearance. Inclisiran bypasses all four in the conventional sense. It is delivered by injection, so gut absorption is irrelevant. Plasma protein binding is moderate but not saturable at therapeutic doses. The drug is metabolized by nucleases into short oligonucleotide fragments, not by CYP3A4 or CYP2C19. Renal excretion of intact drug is minimal. A 2020 pharmacokinetic analysis in Clinical Pharmacokinetics [2] confirmed that inclisiran's distribution and elimination are dominated by hepatic uptake and intracellular nuclease activity, making conventional metabolic drug interactions essentially non-applicable.

The ORION Trial Program Confirms a Favorable Safety Signal

The ORION phase 3 program enrolled more than 3,600 patients across ORION-9, ORION-10, and ORION-11. In ORION-10 (N=1,561 patients with ASCVD), inclisiran 284 mg produced a time-averaged LDL-C reduction of 52.3% versus placebo at day 510 (P<0.0001). The NEJM publication of ORION-10 [3] reported that adverse events were comparable between active and placebo groups, with injection-site reactions being the most common drug-related event. Across these trials, no patient subgroup using B-vitamin or folate supplements was flagged for a safety signal.

What Folate Does in the Body

Folate is a water-soluble B-vitamin (B9) required for one-carbon transfer reactions, DNA synthesis, and the remethylation of homocysteine to methionine. Dietary folate from food and supplemental folic acid must be converted to the active form, 5-methyltetrahydrofolate (5-MTHF), before use. The NIH Office of Dietary Supplements fact sheet on folate [4] states that the recommended dietary allowance for adults is 400 mcg dietary folate equivalents (DFE) per day, rising to 600 mcg DFE during pregnancy.

MTHFR Variants and the Case for Methylfolate

Roughly 10 to 15 percent of people of European ancestry carry two copies of the MTHFR C677T variant, reducing MTHFR enzyme activity by approximately 70 percent. A large meta-analysis in the American Journal of Clinical Nutrition (N=21,523 subjects) [5] found that homozygous MTHFR C677T carriers had significantly higher plasma homocysteine. For these individuals, bypassing the conversion step with L-methylfolate (the pre-reduced, bioavailable form) may be preferable to standard folic acid. This consideration is entirely separate from inclisiran therapy and does not change Leqvio dosing or timing.

Folate and Cardiovascular Risk: Relevant Background for Leqvio Patients

Patients prescribed inclisiran carry elevated cardiovascular risk by definition. Elevated homocysteine is an independent, though modest, cardiovascular risk marker. The JAMA-published VISP trial (N=3,680) [6] examined whether high-dose B-vitamin therapy (including folate 2.5 mg daily) lowered stroke risk in patients with recent ischemic stroke and found no significant benefit over low-dose supplementation despite meaningful homocysteine reduction. This does not mean folate is harmful in ASCVD patients; it means folate's cardiovascular effect is largely neutral at the clinical endpoint level. Leqvio addresses LDL-C specifically, and the two interventions operate on different risk factors without interference.

Pharmacokinetic Analysis: Does Folate Affect Inclisiran Levels?

The short answer is no. Folate enters cells via the reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT), and its metabolic fate runs through the one-carbon cycle in the cytoplasm and mitochondria. Inclisiran, once injected, travels to the liver and is internalized via asialoglycoprotein receptors thanks to its GalNAc ligand. A 2019 paper in the New England Journal of Medicine describing the inclisiran mechanism [3] illustrates that the drug's intracellular machinery (RISC complex, Argonaute-2) has no known interaction with folate-dependent enzymes or transporters.

No Shared Transporters

Folate transporters (RFC1, PCFT) and the GalNAc-hepatocyte receptor system serve completely different substrate classes. Competitive inhibition at shared transporters, the mechanism behind methotrexate-folate interactions for instance, simply does not apply here. Methotrexate blocks dihydrofolate reductase (DHFR) and RFC1, which is why leucovorin rescue is needed in high-dose chemotherapy. Inclisiran does not touch DHFR, RFC1, or any folate-cycle enzyme.

No CYP450 Overlap

Folic acid and its metabolites are not processed through cytochrome P450 enzymes in ways that would compete with inclisiran elimination. The FDA Drug Interactions guidance for industry [7] classifies drugs as CYP interaction risks only when they are substrates, inducers, or inhibitors of specific isoforms. Inclisiran is not a CYP substrate. Folate is not a CYP inducer or inhibitor at physiological doses. No overlap exists.

Pharmacodynamic Analysis: Do Their Effects Conflict?

Pharmacodynamic interactions occur when two agents act on overlapping biological targets, producing additive, synergistic, or antagonistic effects. Inclisiran silences PCSK9, leading to upregulated LDL receptors on hepatocytes and increased LDL-C clearance. Folate supports homocysteine remethylation and one-carbon metabolism. These pathways do not converge on the same receptor, enzyme, or downstream signal.

Homocysteine and LDL Receptors: No Cross-Talk

Some researchers have asked whether elevated homocysteine might reduce LDL receptor expression, theoretically diminishing inclisiran's effect. A 2004 review in Arteriosclerosis, Thrombosis, and Vascular Biology [8] examined homocysteine's effects on endothelial function and found effects on oxidative stress and endothelial dysfunction, but no evidence of clinically meaningful LDL receptor suppression. Folate supplementation that reduces homocysteine would therefore not enhance or antagonize inclisiran's mechanism.

Lipid Panels Stay Interpretable

Some supplements alter total cholesterol or triglycerides and can confound lipid monitoring. Folate does not meaningfully shift LDL-C, HDL-C, or triglycerides in the doses used clinically. The Cochrane review on folate supplementation and cardiovascular biomarkers [9] found no consistent effect of folate on serum lipid concentrations across 13 trials. Your 3-month post-injection lipid panel will accurately reflect inclisiran's response.

Special Populations and Edge Cases

Patients on Anticonvulsants

Certain anticonvulsants (phenytoin, carbamazepine, valproate, phenobarbital) deplete folate by accelerating its metabolism or impairing absorption. Patients who take both an anticonvulsant and inclisiran for ASCVD may need higher folate supplementation, sometimes 1 to 5 mg folic acid daily, to avoid deficiency. The American Academy of Neurology guideline on women with epilepsy [10] recommends at least 0.4 to 4 mg of folic acid daily in women of childbearing age on enzyme-inducing anticonvulsants. The anticonvulsant is the relevant interaction partner here, not inclisiran.

Patients with MTHFR Variants

If you carry MTHFR C677T (homozygous) and take standard folic acid at doses above 400 mcg, unmetabolized folic acid (UMFA) may accumulate. A 2017 study in the American Journal of Clinical Nutrition [11] found detectable UMFA in plasma after supplementation with 400 mcg or more of folic acid in C677T homozygotes. Switching to L-methylfolate (sold as Deplin, Metanx, or generic 5-MTHF) avoids UMFA accumulation. Again, inclisiran does not change this decision; it is a folate-specific consideration.

Pregnancy and Periconceptional Use

Women of childbearing age who are on inclisiran (off-label or in trials) and wish to become pregnant should follow standard periconceptional guidance of 400 to 800 mcg folic acid daily. Inclisiran's reproductive safety data are limited; the FDA label advises against use during pregnancy. The folate requirement stands regardless of inclisiran status. The CDC recommends [12] that all women capable of becoming pregnant consume 400 mcg of folic acid daily to reduce neural tube defect risk.

Renal Impairment

Patients with chronic kidney disease (CKD) on inclisiran may have folate deficiency due to urinary losses, especially those on hemodialysis. A study in the Journal of the American Society of Nephrology [13] found that dialysis patients lose substantial water-soluble vitamins during each session, making daily folate replacement (1 mg) standard practice. Inclisiran's PK is not altered by severe renal impairment per the Leqvio prescribing information [1], and folate supplementation in this group remains appropriate.

Practical Dosing and Monitoring Guidance

The table below summarizes how to manage folate use alongside Leqvio based on patient profile.

| Patient Profile | Recommended Folate Form | Daily Dose Range | Timing Relative to Leqvio Injection | |---|---|---|---| | General adult, no MTHFR variant | Folic acid | 400 to 800 mcg | Any time; no separation needed | | MTHFR C677T homozygous | L-methylfolate (5-MTHF) | 400 mcg to 1 mg | Any time; no separation needed | | On enzyme-inducing anticonvulsants | Folic acid or 5-MTHF | 1 to 5 mg | Any time; discuss with neurologist | | CKD on hemodialysis | Folic acid | 1 mg | Any time; standard renal vitamin protocol | | Periconceptional | Folic acid | 400 to 800 mcg | Standard periconceptional protocol |

Inclisiran is dosed on day 1, day 90, and then every 6 months by subcutaneous injection in a clinical setting. Because no dose-separation window is needed, patients do not need to pause or time folate around injection appointments.

What to Monitor

• LDL-C at approximately 3 months after each inclisiran dose to confirm response.
• Serum folate and red blood cell folate annually if dietary intake is uncertain or deficiency symptoms appear (fatigue, macrocytic anemia, glossitis).
• Homocysteine level optionally, particularly in patients with CKD, MTHFR variants, or anticonvulsant use.
• Complete blood count (CBC) if megadose folate (>5 mg daily) is used, as high-dose folate can mask vitamin B12 deficiency by correcting macrocytosis without correcting neurological damage. The NIH ODS folate fact sheet [4] flags this risk explicitly.

Reporting Folate Use to Your Prescriber

Even though no interaction exists, your Leqvio prescriber should have a complete supplement list. The American Heart Association's 2023 primary prevention guideline [14] recommends that clinicians document all supplements at each cardiovascular risk review because some B-vitamin formulations (particularly high-dose niacin combinations) can alter lipid fractions and confound statin or PCSK9 inhibitor monitoring. Pure folate supplements do not cause this issue, but documentation supports comprehensive care.

What the Leqvio Prescribing Information Says About Supplements

The FDA-approved prescribing information for inclisiran [1] does not list folate, folic acid, methylfolate, or any B-vitamin as a contraindicated or cautioned co-medication. The drug interactions section specifies no CYP450-based interactions, no transporter interactions, and no protein-binding displacement concerns. The absence of a warning, combined with the mechanistic analysis above, gives clinicians a reasonable basis to conclude that folate co-administration is safe.

The prescribing information does note that inclisiran is not recommended in patients with severe hepatic impairment, since hepatic uptake is required for the drug to reach its intracellular target. Folate metabolism in severe liver disease may also be impaired, but this is a liver-function issue, not an inclisiran-folate interaction.

Clinical Bottom Line Before the FAQ

Folate and inclisiran operate in entirely separate biological compartments. No pharmacokinetic overlap exists at the transporter, enzyme, or clearance level. No pharmacodynamic conflict exists at the receptor or pathway level. Patients with HeFH or ASCVD on Leqvio 284 mg can take 400 mcg to 5 mg of folate daily without adjusting the Leqvio injection schedule. The one exception worth discussing with a provider is the choice between folic acid and L-methylfolate in confirmed MTHFR C677T homozygotes, but that discussion centers on folate bioavailability, not on Leqvio safety. Check your LDL-C at the 3-month post-injection mark; a <50% reduction from baseline may warrant a conversation about statin dose optimization or additional therapy per the 2022 ACC/AHA cholesterol guideline. That guideline [15] targets an LDL-C of <70 mg/dL in very high-risk ASCVD patients, with inclisiran recommended when that threshold is not met on statin plus ezetimibe.